Cantor Fitzgerald sets $20 price target for 4D Molecular Therapeutics
Cantor Fitzgerald raised 4D Molecular Therapeutics to Overweight from Neutral and announced a $20.00/share price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.